Arcturus Therapeutics Gets $3M From Cystic Fibrosis Foundation

San Diego-based Arcturus Therapeutics, a developer of mRNA-based treatments for disease, has signed a deal to receive up to $3M in funding from the Cystic Fibrosis Foundation Therapeutics, a nonprofit which supports drug discovery and development. The company said the $3M will go to advance LUNAR-CF, a novel messenger RNA (mRNA) therapeutic formulated with Arcturus' drug delivery technology. Arcturus said the effort will support discovery and development of mRNA therapeutics that aim to enable cells of CF patients to restore the function of their cystic fibrosis transmembrane conductance regulator, or CFTR, gene in their lungs.